Entero Therapeutics names new interim CEO after leadership change

Entero Therapeutics Inc. (NASDAQ: ENTO) terminated Richard Joel Paolone as interim chief executive officer and chairman of the board without cause on September 3, 2025, according to a company statement.

The company said Paolone's termination was not due to any disagreement regarding financial reporting, policies or practices. He remains a director on the board.

Entero Therapeutics also terminated Paolone's consulting agreement with the company, dated February 12, 2025, without cause and with payment in lieu of the contractual notice period.

Jason D. Sawyer was appointed interim chief executive officer on September 4, 2025, effective immediately. Sawyer continues to serve as a director on the company's board.

You May Also Be Interested In

• Getty Realty discloses separation terms for departing accounting officer
• James Hardie sells Fermacell unit to Holcim for €840 million
• ICE raises $3.71 billion in senior notes to fund MarketAxess deal